首页> 外文期刊>British Journal of Pharmacology >The antimigraine 5-HT_(1B/1D) receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain
【24h】

The antimigraine 5-HT_(1B/1D) receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain

机译:抗偏头痛5-HT_(1B / 1D)受体激动剂舒马曲坦,佐米曲普坦和二氢麦角胺在三叉神经痛大鼠模型中减轻与疼痛有关的行为

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

1. Peripheral lesion to the trigeminal nerve may induce severe pain states. Several lines of evidence have suggested that the antimigraine effect of the triptans with 5-HT_(1B/1D) receptor agonist properties may result from inhibition of nociceptive transmission in the spinal nucleus of the trigeminal nerve by these drugs. On this basis, we have assessed the potential antinociceptive effects of sumatriptan and zolmitriptan, compared to dihydroergotamine (DHE), in a rat model of trigeminal neuropathic pain. 2. Chronic constriction injury was produced by two loose ligatures of the infraorbital nerve on the right side. Responsiveness to von Frey filament stimulation of the vibrissal pad was used to evaluate allodynia. 3. Two weeks after ligatures, rats with a chronic constriction of the right infraorbital nerve displayed bilateral mechanical hyper-responsiveness to von Frey filament stimulation of the vibrissal pad with a mean threshold of 0.38 +- 0.04g on the injured side and of 0.43 +- 0.04g on the contralateral (left) side (versus ≥ 12.5g on both sides in the same rats prior to nerve constriction injury). 4. Sumatriptan at a clinically relevant dose (100 μg kg~(-1), s.c.) led to a significant reduction of the mechanical allodynia-like behaviour on both the injured and the contralateral sides (peak-effects 6.3 +- 1.1g and 4.4 +- 0.7g, respectively). A more pronounced effect was obtained with zolmitriptan (100 μg kg~(-1), s.c.) (peak-effects: 7.4 +- 0.9g and 3.2 +- 1.3g) whereas DHE (50-100 μg kg~(-1), i.v.) was less active (peak-effect ~1.5g). 5. Subcutaneous pretreatment with the 5-HT_(1B/1D) receptor antagonist, GR 127935 (3 mg kg~(-1)), prevented the anti-allodynia-like effects of triptans and DHE. Pretreatment with the 5-HT_(1A) receptor antagonist, WAY 100635 (2mg kg~(-1), s.c.), did not alter the effect of triptans but significantly enhanced that of DHE (peak effect 4.3 +- 0.5g). 6. In a rat model of peripheral neuropathic pain, which consisted of a unilateral loose constriction of the sciatic nerve, neither sumatriptan (50-300 μg kg~(-1)) nor zolmitriptan (50-300 μg kg~(-1)) modified the thresholds for paw withdrawal and vocalization in response to noxious mechanical stimulation. 7. These results support the rationale for exploring the clinical efficacy of brain penetrant 5-HT_(1B/1D) receptor agonists as analgesics to reduce certain types of trigeminal neuropathic pain in humans.
机译:1.三叉神经的周围病变可能导致严重的疼痛状态。几条证据表明,具有5-HT_(1B / 1D)受体激动剂特性的曲普坦类药物的偏头痛作用可能是由于这些药物抑制了三叉神经脊髓核中的伤害性传递。在此基础上,我们评估了三叉神经痛大鼠模型中舒马曲坦和佐米曲普坦与二氢麦角胺(DHE)相比潜在的镇痛作用。 2.右侧眶下神经的两个松散结扎产生了慢性压迫性损伤。对震动垫的冯·弗雷丝刺激的反应性用于评估异常性疼痛。 3.结扎后两周,患有右眶下神经慢性收缩的大鼠表现出对震颤垫的von Frey细丝刺激的双侧机械性高反应性,受伤侧的平均阈值为0.38 +-0.04g,0.43 + -对侧(左侧)0.04g(在神经收缩损伤之前同一只大鼠的两侧≥12.5g)。 4.临床剂量的舒马普坦(100μgkg〜(-1),皮下注射)导致受伤侧和对侧的机械性异常性疼痛样行为明显减少(峰值效应6.3 +-1.1g和分别为4.4±0.7克)。佐米曲普坦(100μgkg〜(-1),sc)获得了更明显的效果(峰值效应:7.4±0.9 g和3.2±1.3 g),而DHE(50-100μgkg〜(-1)) ,iv)的活性较弱(峰值效果〜1.5g)。 5.用5-HT_(1B / 1D)受体拮抗剂GR 127935(3 mg kg〜(-1))进行皮下预处理可预防曲普坦和DHE的抗异常性疼痛作用。用5-HT_(1A)受体拮抗剂WAY 100635(2mg kg〜(-1),s.c.)预处理不会改变曲普坦的作用,但会显着增强DHE的作用(峰值作用4.3±0.5g)。 6.在周围神经性疼痛的大鼠模型中,该模型由坐骨神经的单侧松弛性收缩组成,舒马曲坦(50-300μgkg〜(-1))和佐米曲普坦(50-300μgkg〜(-1)均不)响应有害的机械刺激,修改了缩爪和发声的阈值。 7.这些结果支持了探索脑渗透剂5-HT_(1B / 1D)受体激动剂作为镇痛药以减轻人类某些类型的三叉神经痛的临床疗效的理由。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号